Back to Browse Journals » OncoTargets and Therapy » Volume 3

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

Authors Carmen Diana Schweighofer, Clemens-Martin Wendtner

Published 30 March 2010 Volume 2010:3 Pages 53—67


Review by Single-blind

Peer reviewer comments 2

Carmen Diana Schweighofer1, Clemens-Martin Wendtner2

1Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA; 2Department of Internal Medicine I, University of Cologne, Cologne, Germany

Abstract: The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved as a first-line single agent, even though the hurdle with chlorambucil as the contender was not set very high. Within clinical trials, the drug demonstrated an excellent ability to eliminate minimal residual disease in blood and bone marrow, which has been correlated with a corresponding survival advantage in patients. However, in the maintenance setting, infectious complications due to severe T cell suppression have been highlighted and do not allow clinicans to use alemtuzumab outside of clinical trials. This review discusses potential therapeutic niches and future applications of alemtuzumab with a focus on CLL front-line treatment.
Keywords: CLL, alemtuzumab, Campath, front-line, first-line treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Toxicology of antimicrobial nanoparticlesfor prosthetic devices

Nuñez-Anita RE, Acosta-Torres LS, Vilar-Pineda J, Martínez-Espinosa JC, de la Fuente-Hernández J, Castaño VM

International Journal of Nanomedicine 2014, 9:3999-4006

Published Date: 20 August 2014

Functionalized graphene oxide for clinical glucose biosensing in urine and serum samples

Veerapandian M, Seo YT, Shin H, Yun K, Lee MH

International Journal of Nanomedicine 2012, 7:6123-6136

Published Date: 18 December 2012

Tumor necrosis factor signaling is implicated in intestinal mucosal injury of cancer cachexic mice

Jia Y, Tian W, Cui B

OncoTargets and Therapy 2012, 5:343-348

Published Date: 12 November 2012

Composite scaffolds of mesoporous bioactive glass and polyamide for bone repair

Su J, Cao L, Yu B, Song S, Liu X, Wang Z, Li M

International Journal of Nanomedicine 2012, 7:2547-2555

Published Date: 21 May 2012

Cyclodextrin-erythromycin complexes as a drug delivery device for orthopedic application

Song W, Yu X, Wang S, Blasier R, Markel DC, Mao G, Shi T, Ren W

International Journal of Nanomedicine 2011, 6:3173-3186

Published Date: 8 December 2011

Tat peptide-admixed elastic liposomal formulation of hirsutenone for the treatment of atopic dermatitis in Nc/Nga mice

Kang MJ, Eum JY, Jeong MS, Park SH, Moon KY, Kang MH, Kim MS, Choi SE, Lee MW, Lee DI, Bang H, Lee CS, Joo SS, Li K, Lee M-K, Seo SJ, Choi YW

International Journal of Nanomedicine 2011, 6:2459-2467

Published Date: 20 October 2011

Development of enteric submicron particle formulation of papain for oral delivery

Sharma M, Sharma V, Panda AK, Majumdar DK

International Journal of Nanomedicine 2011, 6:2097-2111

Published Date: 23 September 2011

Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery

Yin-Ku Lin, Zih-Rou Huang, Rou-Zi Zhuo, et al

International Journal of Nanomedicine 2010, 5:117-128

Published Date: 25 February 2010

Structure-based design of anticancer prodrug PABA/NO

Xinhua Ji, Ajai Pal, Ravi Kalathur, Xun Hu, Yijun Gu, et al

Drug Design, Development and Therapy 2008, 2:123-130

Published Date: 11 August 2008